Cancer vaccines have been considered promising therapeutic strategies and are often constructed from whole cells, attenuated pathogens, carbohydrates, peptides, nucleic acids, etc. However, the use of whole organisms or pathogens can elicit unwanted immune responses arising from unforeseen reactions to the vaccine components. On the other hand, synthetic vaccines, which contain antigens that are conjugated, often with carrier proteins, can overcome these issues. Therefore, in this review we have highlighted the synthetic approaches and discussed several bioconjugation strategies for developing antigen-based cancer vaccines. In addition, the major synthetic biology approaches that were used to develop genetically modified cancer vaccines and their progress in clinical research are summarized here. Furthermore, to boost the immune responses of any vaccines, the addition of suitable adjuvants and a proper delivery system are essential. Hence, this review also mentions the synthesis of adjuvants and utilization of biomaterial scaffolds, which may facilitate the design of future cancer vaccines.
This investigation compares paclitaxel pharmacokinetics using 7 strains of mice and 2 routes of administration and longitudinally explores pharmacodynamics using 2 representative strains, which informs cross-study comparisons and the validation of translationally relevant model systems. These findings support the notion that accumulation within dorsal root ganglia, rather than plasma exposure, is correlated with the development of peripheral neuropathy. This insight is anticipated to guide the future development of effective therapeutic strategies for managing paclitaxel-induced peripheral neuropathy.